{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:54Z","timestamp":1786650054484,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Allo-Hematopoietic Stem Cell Transplantation (HSCT) offers a curative option for relapsed and refractory multiple myeloma in younger aged and fit patients with high-risk cytogenetic properties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>This study retrospectively enrolled the medical data of 30 patients who had undergone allogeneic stem cell transplantation at the Gazi University Adult Stem Cell Transplant Unit between 2005 and 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Before allo-SCT, 6 (20.0%) patients were in complete remission; 8 (26.6%) had a partial response; 14 (46.6%) had progressive disease, and 2 (6.6%) had stable disease. Overall survival (OS) at 1, 2, 3, and 5 years post-transplant were 45%, 36.3%, 31.7%, and 22.7%, respectively; transplant-related mortality (TRM) was 25.0% at 100 days. While the 5-year OS was 11.7% in the group with less than PR according to the pre-transplant disease status, it was found to be statistically significant as 45.8% in the group with CR or PR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). TRM was significantly higher in patients with less than PR compared has CR or PR at pre-transplantation (100% vs. 43.7%\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01). Like these findings, PFS was shorter in patients with less than PR compared has CR or PR at pre-transplantation (6.2 vs. 77.1 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We found longer OS and PFS in patients with a complete response before allo-SCT. This shows that the depth of response before allogeneic stem cell transplantation is effective on 100-day TRM in multiple myeloma patients. Allo-HSCT may be a therapeutic option in MM patients who relapse\/refractory after auto-SCT, particularly after achieving the least partial response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_107_24","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T01:00:32Z","timestamp":1741050032000},"page":"1405-1409","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Refractory Multiple Myeloma"],"prefix":"10.4103","volume":"27","author":[{"given":"HBA","family":"\u00d6zt\u00fcrk","sequence":"first","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AA","family":"Dikyar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZA","family":"Ye\u011fin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gazi University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LA","family":"Kaynar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Bilkent City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZN","family":"\u00d6zkurt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gazi University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"R1-20260423","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","article-title":"Molecular remission after allogeneic or autologous transplantation of hematopoietic cells for multiple myeloma","volume":"18","author":"Martinelli","year":"2000","journal-title":"J Clin Oncol"},{"key":"R2-20260423","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Chronic leukemia working party of the European Group for blood and Marrow transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"R3-20260423","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation","volume":"88","author":"Bj\u00f6rkstrand","year":"1996","journal-title":"Blood"},{"key":"R4-20260423","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"European Group for Blood and Marrow Transplantation. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"R5-20260423","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"R6-20260423","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"R8-20260423","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"4 Suppl 4","key":"R9-20260423","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.seminhematol.2003.09.010","article-title":"The role of immunomodulatory drugs in multiple myeloma","volume":"40","author":"Anderson","year":"2003","journal-title":"Semin Hematol"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-20260423","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in longterm survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"R12-20260423","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1182\/blood-2010-02-271338","article-title":"Refining \u201ctotal therapy\u201d for myeloma","volume":"115","author":"Blade","year":"2010","journal-title":"Blood"},{"key":"R13-20260423","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.transci.2016.01.015","article-title":"Is it possible to cure myeloma without allogeneic transplantation?","volume":"54","author":"Katodritou","year":"2016","journal-title":"Transfus Apheresis Sci"},{"key":"R14-20260423","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/bmt.2009.141","article-title":"Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe 2009","volume":"45","author":"Ljungman","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"R15-20260423","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11899-017-0374-1","article-title":"Allogeneic hematopoietic cell transplantation for myeloma: When and in whom does it work","volume":"12","author":"Bashir","year":"2017","journal-title":"Current Hematol Malignancy Rep"},{"key":"R16-20260423","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"key":"R17-20260423","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"key":"R18-20260423","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the chronic leukaemia working party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"R19-20260423","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2016.03.001","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: Impact of disease risk and post allograft minimal residual disease on survival","volume":"16","author":"Dhakal","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R20-20260423","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-018-0553-8","article-title":"Allogeneic stem-cell transplantation for multiple myeloma: A systematic review and meta-analysis from 2007 to 2017","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int"},{"key":"R21-20260423","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/leu.2012.282","article-title":"Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project","volume":"27","author":"Avet-Loiseau","year":"2013","journal-title":"Leukemia"},{"key":"R22-20260423","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: Incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_107_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:31Z","timestamp":1786647691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_107_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_107_24","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-02-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}